Genelux Corp.(NASDAQ:GNLX) 
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac...
Website: https://www.genelux.com
Founded: 2001
IPO Price: $6 (Jan 26, 2023)
Full Time Employees: 15
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 2.48
H 2.55
L 2.33
C 2.39
V 321,114
10EMA 2.39
20EMA 2.39
60EMA 2.39
120EMA 2.39
250EMA 2.39